Compare KGEI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KGEI | ACOG |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.1M | 130.9M |
| IPO Year | N/A | N/A |
| Metric | KGEI | ACOG |
|---|---|---|
| Price | $4.11 | $6.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $11.00 | ★ $18.00 |
| AVG Volume (30 Days) | 71.3K | ★ 97.8K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.99 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $60,121,000.00 | $7,427,199.00 |
| Revenue This Year | $6.94 | N/A |
| Revenue Next Year | $14.53 | $143.70 |
| P/E Ratio | $8.31 | ★ N/A |
| Revenue Growth | ★ 10.00 | N/A |
| 52 Week Low | $3.71 | $3.75 |
| 52 Week High | $9.89 | $11.54 |
| Indicator | KGEI | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 55.73 |
| Support Level | $3.94 | $5.66 |
| Resistance Level | $4.11 | $6.18 |
| Average True Range (ATR) | 0.15 | 0.41 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 89.72 | 97.78 |
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.